-+ 0.00%
-+ 0.00%
-+ 0.00%

Radiopharm Theranostics partners with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trial

PUBT·07/22/2026 11:00:53
Listen to the news
Radiopharm Theranostics partners with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trial
  • Radiopharm Theranostics partnered with Siemens Healthineers to manufacture and distribute 18F-labeled RAD101 doses for a planned U.S. Phase 3 pivotal trial.
  • Collaboration follows Phase 2b results showing 93% concordance between RAD101 PET and MRI across evaluable lesions.
  • Radiopharm targets Phase 3 initiation in Q4 2026; RAD101 holds FDA Fast Track designation for recurrent brain metastases imaging.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220700PRIMZONEFULLFEED1001213823) on July 22, 2026, and is solely responsible for the information contained therein.